Navigation Links
Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
Date:9/30/2013

ALEXANDRIA, Va., Sept. 30, 2013 /PRNewswire/ -- Food and Drug Administration (FDA) announced the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab). The Boxed Warning is specific to the risk of reactivating hepatitis B virus (HBV) in patients who were previously infected with the virus. Use of these drugs in patients with prior HBV infection can result in severe liver damage if the virus is reactivated.

The American Association for the Study of Liver Diseases represents the hepatology community, which has recognized for more than a decade that treatment of cancer with chemotherapy sometimes results in reactivation of HBV. The risk of HBV reactivation is already described in the Warnings and Precautions section of the labels for both drugs; however, the FDA's monitoring system had continued to detect cases of HBV reactivation with these agents and independently came to appreciate the problem's persistence.

AASLD convened a conference on the subject of HBV reactivation during chemotherapy in March 2013, and representatives of the FDA were present at the meeting and engaged in discussions. Those discussions between AASLD and the FDA were continued through the summer. According to AASLD President-Elect Adrian Di Bisceglie, MD, "AASLD members were recognized as experts and our persistence as an organization in this area helped FDA make up its mind to notify prescribing physicians of this problem."

The FDA also released new recommendations to decrease the risk of HBV reactivation when these drugs are used. Addressing this risk of hepatitis B reactivation, the full FDA communication states: "The revised labels will include additional recommendations for screening, monitoring, and managing these patients on these drugs to decrease this risk."

The Warnings and Precautions section is being revised for each drug to express new recommendations for health care professionals. Dr. Di Bisceglie added, "We still believe there are other agents and treatment regimens that pose similar risks of HBV reactivation, and AASLD will call for further study and awareness of this and other agents may perhaps need similar box warnings."

Please follow this link for the FDA press release and additional information on HBV reactivation: http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm.

 

AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.

Press releases and additional information about AASLD are available online at www.aasld.org.

Media Contact: Gregory Bologna
703/299-9766
gbologna@aasld.org

 

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
2. Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals
3. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
4. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
5. Bulgaria Launches Development of National Hepatitis Plan
6. Major Breakthrough in Hepatitis C Vaccine Development
7. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
10. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
11. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 4, 2016 Global ... pages, profiling 09 key companies and supported with ... and in-depth study on the current state of ... of the industry including definitions, classifications, applications and ... is provided for the international market including development ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... May 4, 2016 Research and ... Cancer Stem Cell Therapy Market Outlook 2020" report ... ) , ,Recombinant technology has improved significantly in ... to be developed in coming years. Many cancer drugs ... stem cell therapies are also expected to be developed ...
Breaking Medicine Technology:
(Date:5/3/2016)... Minnesota (PRWEB) , ... May 04, 2016 , ... ... more than 40 national and global construction firms representing the Construction Industry Safety ... have joined forces with one purpose: to inspire everyone in the industry to ...
(Date:5/3/2016)... (PRWEB) , ... May 04, 2016 , ... ... for cancer. That message is reaching the global health community through expanding activities ... the burden of cancer in the resource-limited countries. , In support ...
(Date:5/3/2016)... , ... May 04, 2016 , ... The National ... inductee into its VIP Woman of the Year Circle. She is recognized with this ... for professional women, boasting more than 850,000 members and over 200 operating Local Chapters. ...
(Date:5/3/2016)... Viejo, CA (PRWEB) , ... May 03, 2016 , ... ... in Final Cut Pro X. Pixel Film Studios’ titles allow users to add a ... and basic elements such as boxes, lines and accents. To add greater contrast, all ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Journal, patients report dissatisfaction with numerous issues related to medical care in the ... billing, and poor bedside manner from hospital staff. Commenting on this article, the ...
Breaking Medicine News(10 mins):